Natera Inc. holds an estimated 80% market share in the minimal residual disease (MRD) testing market. The company’s flagship Signatera product uses personalized liquid biopsies to detect circulating tumor DNA (ctDNA) in blood.
This technology identifies cancer recurrence months or years earlier than traditional imaging scans. Early detection allows oncologists to intervene sooner and personalize post-treatment therapies.
The MRD detection market is forecast to expand significantly. Natera maintains its dominant position against competitors like Guardant Health through extensive clinical validation and growing oncologist adoption.